# US 12,599,497 B2 · Implants with controlled drug delivery features and methods of using same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,599,497 B2 - Document ID: US12599497B2 - Status: Granted - Kind: B2 - Application number: 18/151,816 - Filed: 2023-01-09 - Published: 2023-05-25 - Granted: 2026-04-14 - Earliest claimed: 2013-03-15 - Assignees: Glaukos Corporation - Applicants: Glaukos Corporation - Inventors: David S. Haffner; Thomas W. Burns; Harold A. Heitzmann; Kenneth M. Curry - Web page: https://patentgrep.com/patent/US12599497B2 ## CPC - A61F 9/0017: {implantable in, or in contact with, the eye, e.g. ocular inserts} - A61F 9/00781: {Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment (drainage implants in general A61M27/002)} - A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) ## Abstract Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device. ## Claims ### Claim 1 A method of treating an ocular disorder, comprising: inserting an implant into an eye, the implant comprising: an outer shell defining an interior space, the outer shell having a proximal end and a closed distal end; a permeable or semi-permeable membrane positioned within the interior space of the outer shell; at least one fluid inflow pathway and at least one fluid outflow pathway positioned adjacent the closed distal end of the outer shell; and a retention protrusion extending from the closed distal end; anchoring the retention protrusion of the implant to an intraocular tissue in an anterior chamber of an eye; eluting one or more drugs through the permeable or semi-permeable membrane, wherein the permeable or semi-permeable membrane at least partially controls a rate of elution, and permitting drainage of ocular fluid from the anterior chamber to a physiological outflow space through the at least one fluid inflow pathway and the at least one fluid outflow pathway. ### Claim 2 (depends on 1) The method of claim 1, wherein the physiological outflow space is Schlemm's canal. ### Claim 3 (depends on 1) The method of claim 1, wherein anchoring the retention protrusion to the intraocular tissue further comprises positioned the retention protrusion such that it extends into but not through the intraocular tissue. ### Claim 4 (depends on 1) The method of claim 1, further comprising eluting the one or more drugs through at least one orifice of a cap. ### Claim 5 (depends on 1) The method of claim 1, wherein the retention protrusion comprises ridges, claws, threads, flexible ribs, rivet-like shape, flexible barbs, sharpened tip or barbed tip. ### Claim 6 (depends on 1) The method of claim 1, wherein the implant is inserted using an applicator comprising a handpiece having an elongate tip connected to a distal end of the handpiece. ### Claim 7 (depends on 6) The method of claim 6, wherein inserting the implant further comprises using an actuator disposed on the handpiece to release the implant from a holder positioned at the distal end of the elongate tip. ### Claim 8 A method of treating an ocular disorder, comprising: inserting an implant into an eye, the implant comprising: an outer shell defining an interior space containing at least one drug, the outer shell having a proximal end and a closed distal end; a membrane positioned within the interior space of the outer shell; and at least one fluid inflow pathway and at least one fluid outflow pathway positioned adjacent the closed distal end of the outer shell; anchoring the implant to an intraocular tissue in an anterior chamber of an eye; eluting one or more drugs through the membrane, wherein the membrane at least partially controls a rate of elution; and delivering an ocular fluid from the anterior chamber to a physiological outflow space through the at least one fluid inflow pathway and the at least one fluid outflow pathway. ### Claim 9 (depends on 8) The method of claim 8, wherein the physiological outflow space is Schlemm's canal. ### Claim 10 (depends on 8) The method of claim 8, wherein the implant is anchored to the intraocular tissue using a retention protrusion. ### Claim 11 (depends on 10) The method of claim 10, wherein anchoring the retention protrusion to the intraocular tissue further comprises positioning the retention protrusion such that it extends into but not through the intraocular tissue. ### Claim 12 (depends on 10) The method of claim 10, wherein the retention protrusion comprises ridges, claws, threads, flexible ribs, rivet-like shape, flexible barbs, sharpened tip or barbed tip. ### Claim 13 (depends on 8) The method of claim 8, wherein the implant is inserted using an applicator comprising a handpiece having an elongate tip connected to a distal end of the handpiece. ### Claim 14 (depends on 13) The method of claim 13, wherein inserting the implant further comprises using an actuator disposed on the handpiece to release the implant from a holder positioned at the distal end of the elongate tip.